Thus, instead of interfering with the immune response by affecting tumor neoantigenesis, SEMA4D may lead to immunosuppression mainly by interfering with immune checkpoints in the microenvironment, affecting the effector function of T cells against tumor cells. The gene discussed is SEMA4D; the disease is neoplasm.